The prognostic value of CD133 expression in non-small cell lung cancer: A meta-analysis

Tumor Biology

Volumn 35, Issue 10, 2014, Pages 9769-9775

  Wang, Weimin ^a   Chen, Yansu ^b   Deng, Jianliang ^a   Zhou, Jianping ^a   Zhou, Yan ^a   Wang, Shouyu ^b   Zhou, Jianwei ^b  

^a Yixing People's Hospital   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

CD133; Clinicopathological characteristics; NSCLC; Prognosis

Indexed keywords

CD133 ANTIGEN; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE; TUMOR MARKER;

BIOSYNTHESIS; DISEASE FREE SURVIVAL; HUMAN; LUNG TUMOR; META ANALYSIS; METABOLISM; MORTALITY; NON SMALL CELL LUNG CANCER; PROGNOSIS;

ANTIGENS, CD; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; GLYCOPROTEINS; HUMANS; LUNG NEOPLASMS; PEPTIDES; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84922393099     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2270-9     Document Type: Article

References (27)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Esposito L, Conti D, Ailavajhala R, Khalil N, Giordano A. Lung cancer: are we up to the challenge? Curr Genomics. 2010; 11: 513-8.
3. Alberg AJ, Ford JG, Samet JM. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007; 132: 29S-55.
4. Dontu G, Liu S, Wicha MS. Stem cells in mammary development and carcinogenesis: implications for prevention and treatment. Stem Cell Rev. 2005; 1: 207-13.
5. Ribatti D. Cancer stem cells and tumor angiogenesis. Cancer Lett. 2012; 321: 13-7.
6. Baccelli I, Trumpp A. The evolving concept of cancer and metastasis stem cells. J Cell Biol. 2012; 198: 281-93.
7. Perona R, Lopez-Ayllon BD, de Castro Carpeno J, Belda-Iniesta C. A role for cancer stem cells in drug resistance and metastasis in nonsmall-cell lung cancer. Clin Transl Oncol. 2011; 13: 289-93.
8. Kitamura H, OkudelaK, Yazawa T, Sato H, Shimoyamada H. Cancer stem cell: implications in cancer biology and therapy with special reference to lung cancer. Lung Cancer. 2009; 66: 275-81.
9. SalnikovAV, Gladkich J, Moldenhauer G, VolmM, Mattern J, Herr I. Cd133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int J Cancer J Int Cancer. 2010; 126: 950-8.
10. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004; 432: 396-401.
11. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human coloncancer-initiating cells. Nature. 2007; 445: 111-5.
12. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008; 15: 504-14.
13. Arne G, Kristiansson E, Nerman O, Kindblom LG, Ahlman H, Nilsson B, et al. Expression profiling of GIST: CD133 is associated with KIT exon 11 mutations, gastric location and poor prognosis. Int J Cancer J Int Cancer. 2011; 129: 1149-61.
14. Boegl M, Prinz C. Cd133 expression in different stages of gastric adenocarcinoma. Br J Cancer. 2009; 100: 1365-6. author reply 1367.
15. Wu S, Yu L, Wang D, Zhou L, Cheng Z, Chai D, et al. Aberrant expression of CD133 in non-small cell lung cancer and its relationship to vasculogenic mimicry. BMC Cancer. 2012; 12: 535.
16. Woo T, Okudela K, Mitsui H, Yazawa T, Ogawa N, Tajiri M, et al. Prognostic value of CD133 expression in stage i lung adenocarcinomas. Int J Clin Exp Pathol. 2010; 4: 32-42.
17. Mizugaki H, Sakakibara-Konishi J, Kikuchi J, Moriya J, Hatanaka KC, Kikuchi E, Kinoshita I, Oizumi S, Dosaka-Akita H, Matsuno Y, Nishimura M. Cd133 expression: A potential prognostic marker for non-small cell lung cancers. Int J Clin Oncol. 2013.
18. Sullivan JP, SpinolaM, DodgeM, RasoMG, Behrens C, Gao B, et al. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res. 2010; 70: 9937-48.
19. Yang X, Takano Y, Zheng HC. The pathobiological features of gastrointestinal cancers (review). Oncol Lett. 2012; 3: 961-9.
20. Liu L, Wu C, Wang Y, Zhong R, Duan S, Wei S, et al. Combined effect of genetic polymorphisms in p53, p73, and mdm2 on non-small cell lung cancer survival. J Thorac Oncol. 2011; 6: 1793-800.
21. Liu L, Yuan P, Wu C, Zhang X, Wang F, Guo H, et al. Assessment of XPD Lys751gln and XRCC1 t-77c polymorphisms in advanced nonsmall-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer. 2011; 73: 110-5.
22. Chen S, Song X, Chen Z, Li X, LiM, Liu H, et al. CD133 expression and the prognosis of colorectal cancer: a systematic review and metaanalysis. PLoS One. 2013; 8: e56380.
23. Wen L, Chen XZ, Yang K, Chen ZX, Zhang B, Chen JP, et al. Prognostic value of cancer stem cell marker cd133 expression in gastric cancer: a systematic review. PLoS One. 2013; 8: e59154.
24. Liu YP, Yang CJ, HuangMS, Yeh CT, Wu AT, Lee YC, et al. Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating notch signaling. Cancer Res. 2013; 73: 406-16.
25. Lundin A, Driscoll B. Lung cancer stem cells: Progress and prospects. Cancer Lett. 2012.
26. Okudela K, Woo T, Mitsui H, Tajiri M, Masuda M, Ohashi K. Expression of the potential cancer stem cell markers, CD133, CD44, ALDH1, and beta-catenin, in primary lung adenocarcinomatheir prognostic significance. Pathol Int. 2012; 62: 792-801.
27. Xu YH, Zhang GB, Wang JM, Hu HC. B7-H3 and CD133 expression in non-small cell lung cancer and correlation with clinicopathologic factors and prognosis. Saudi Med J. 2010; 31: 980-6.